Latest Content

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

DSM’s future adds biomarkers and context, yet validity remains unresolved—are diagnoses real? Critics urge an evidence-based overhaul.

Experts explain how careful pediatric psychopharmacology and early intervention protect development, curb relapse, and address substance-use risk.

Check out the pipeline updates from May!

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.

Explore psychopharmacologic options for personality disorders in this podcast.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.

Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.

In this CME article, explore a 4-stage framework that detects suicide risk without ideation disclosure, guiding clinicians to spot crisis signs and act fast.

Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.